Memantine and Functional Communication in Alzheimer's Disease: Results of a 12-Week, International, Randomized Clinical Trial

作者：Saxton Judith^*; Hofbauer Robert K; Woodward Michael; Gilchrist Nigel L; Potocnik Felix; Hsu Hai An; Miller Michael L; Pejovic Vojislav; Graham Stephen M; Perhach James L

来源：Journal of Alzheimer's Disease, 2012, 28(1): 109-118.

DOI：10.3233/JAD-2011-110947

• Alzheimer's disease
• American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS)
• communication
• drug therapy
• Functional Linguistic Communication Inventory (FLCI)
• language
• memantine
• randomized controlled trial

Post hoc analyses suggest that memantine treatment may provide communication-related benefits in patients with Alzheimer's disease (AD). In this 12-week, international, randomized, double-blind, placebo-controlled trial of memantine (10 mg bid), the functional communication abilities of patients with AD (MMSE range: 10-19) were assessed using the Functional Linguistic Communication Inventory (FLCI; primary measure). Two combined subscales (Social Communication and Communication of Basic Needs) from the American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS; secondary measure) were administered to caregivers. Treatment-emergent adverse events were also recorded. After 12 weeks, memantine-treated patients (n = 133) demonstrated a non-significant improvement on the FLCI (placebo: -0.6; memantine: 0.7; p = 0.070, LOCF) and a significant improvement on the ASHA FACS (placebo: -5.3; memantine: 0.5; p = 0.022), compared with placebo-treated patients (n = 124). Memantine had a low incidence of adverse events. In patients with moderate AD, memantine treatment improved functional communication, as recognized by caregivers.

• 出版日期2012